HIV antibody characterization as a method to quantify reservoir size during curative interventions

Journal of Infectious Diseases

Volumn 209, Issue 10, 2014, Pages 1613-1617

  Burbelo, Peter D ^a   Bayat, Ahmad ^b   Rhodes, Craig S ^a   Hoh, Rebecca ^c   Martin, Jeffrey N ^c   Fromentin, Rémi ^d   Chomont, Nicolas ^d   Hütter, Gero ^e   Kovacs, Joseph A ^f   Deeks, Steven G ^c  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Vaccine and Gene Therapy Institute of Florida   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

antibodies; elite controllers; HIV 1; HIV 1 persistence; serology; viral reservoirs.

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INTEGRASE; MATRIX PROTEIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS CARRIER; VIRUS NUCLEOCAPSID;

ANTIBODIES; ELITE CONTROLLERS; HIV-1; HIV-1 PERSISTENCE; SEROLOGY; VIRAL RESERVOIRS;

ADULT; DNA, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HIV ANTIBODIES; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNITY, HUMORAL; MALE; STEM CELL TRANSPLANTATION;

EID: 84899573008     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit667     Document Type: Article

References (15)

1. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607-14.
2. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-8.
3. Chun TW, Davey RT Jr., Engel D, Lane HC, Fauci AS. Re-emergence of HIV after stopping therapy. Nature 1999; 401:874-5.
4. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
5. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replicationcompetent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
6. Buckheit RW 3rd, Salgado M, Martins KO, Blankson JN. The implications of viral reservoirs on the elite control of HIV-1 infection. Cell Mol Life Sci 2013; 70:1009-19.
7. Mendoza D, Johnson SA, Peterson BA, et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood 2012; 119:4645-55.
8. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-8.
9. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011; 117:2791-9.
10. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin Patient. PLOS Pathog 2013; 9:e1003347.
11. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLOS Pathog 2013; 9: e1003174.
12. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
13. Burbelo PD, Ching KH, Mattson TL, Light JS, Bishop LR, Kovacs JA. Rapid antibody quantification and generation of whole proteome antibody response profiles using LIPS (luciferase immunoprecipitation systems). Biochem Biophys Res Commun 2007; 352:889-95.
14. Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clinical Infect Dis 2005; 40:868-73.
15. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357:1903-15.